Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Tarzana, California Clinical Trials

A listing of Tarzana, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (69) clinical trials

Exercise and Rehabilitation After Traumatic Brain Injury

Exercise-based therapies can promote recovery of function and are easily implemented in the clinical rehabilitation setting. This study will determine if exercise facilitates recovery by improving markers of neuroplasticity and decreasing neuroinflammatory responses. The investigators will also determine if variations in genes involved in neuroplasticity, memory and inflammation influence the ...

Phase

3.57 miles

Learn More »

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

This is an open-label maximum use trial to evaluate ruxolitinib safety and blood levels after its topical application twice daily to affected areas ( 25% BSA) in adolescent and adult participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

Phase

3.57 miles

Learn More »

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

At the end of the study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study. The decision to allow the patient to continue dosing with talazoparib ...

Phase

7.97 miles

Learn More »

Evaluating the Safety and Pharmacokinetics of VRC01 VRC01LS and VRC07-523LS Potent Anti-HIV Neutralizing Monoclonal Antibodies in HIV-1-Exposed Infants

VRC01, VRC01LS, and VRC07-523LS are anti-HIV neutralizing monoclonal antibodies that may help prevent mother-to-child transmission of HIV. This study will enroll HIV-infected mothers who are at increased risk of passing HIV on to their children. The purpose of this study is to assess the safety and PK of VRC01, VRC01LS, ...

Phase

8.19 miles

Learn More »

First-in-human Study of DS-1062a for Advanced Solid Tumors

The dosage strength will change during the study but all participants will receive the same study drug. So the study is not a true 2-arm study, it is a 2-part study. In both parts, subjects with pathologically documented unresectable advanced NSCLC who have been refractory to or relapsed from standard ...

Phase

8.19 miles

Learn More »

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Assignment of patients to a cohort will be based on prior treatment. Participants assigned to Cohort A must have previously received docetaxel for mCRPC. Participants assigned to Cohort B must have previously received either abiraterone acetate or enzalutamide (but not both) in the pre-chemotherapy mCRPC state. Participants assigned to Cohort ...

Phase

8.19 miles

Learn More »

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, UCC, SCCHN and salivary gland cancer) not responding to standard therapy.

Phase

8.19 miles

Learn More »

The purpose of this Study is to evaluate the safety and tolerability of INCB053914 alone and in combination with standard therapies in subjects that have advanced cancer.

Phase

8.19 miles

Learn More »

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

This is a Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 in Subjects with Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII). This is a first in human (FIH), open-label, sequential-dose-escalation study in subjects with EGFRvIII-positive glioblastoma. This study will enroll 2 groups ...

Phase

8.64 miles

Learn More »

A Safety Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase and an expansion phase.

Phase

8.64 miles

Learn More »